title: The Charing Cross Hospital experience with temozolomide in patients with gliomas.
abstract: Temozolomide, a new oral cytotoxic agent, was given to 75 patients with malignant gliomas. The schedule used was for the first course 150 mg/m2 per day for 5 days (i.e. total dose 750 mg/m2), escalating, if no significant myelosuppression was noted on day 22, to 200 mg/m2 per day for 5 days (i.e. total dose 1000 mg/m2) for subsequent courses at 4-week intervals. There were 27 patients with primary disease treated with two courses of temozolomide prior to their radiotherapy and 8 (30%) fulfilled the criteria for an objective response. There were 48 patients whose disease recurred after their initial surgery and radiotherapy and 12 (25%) fulfilled the criteria for an objective response. This gave an overall objective response rate of 20 (27%) out of 75 patients. Temozolomide was generally well tolerated, with little subjective toxicity and predictable myelosuppression. However, the responses induced with this schedule were of short duration and had relatively little impact on overall survival. In conclusion, temozolomide given in this schedule has activity against high grade glioma. However, studies evaluating chemotherapy in primary brain tumours should include a quality-of-life/performance status evaluation in addition to CT or MRI scanning assessment.
authors.affiliation: Department of Medical Oncology, Charing Cross Hospital, London, U.K.
authors.forename: E S
authors.initials: ES
authors.lastname: Newlands
authors.forename: S M
authors.initials: SM
authors.lastname: O'Reilly
authors.forename: M G
authors.initials: MG
authors.lastname: Glaser
authors.forename: M
authors.initials: M
authors.lastname: Bower
authors.forename: H
authors.initials: H
authors.lastname: Evans
authors.forename: C
authors.initials: C
authors.lastname: Brock
authors.forename: M H
authors.initials: MH
authors.lastname: Brampton
authors.forename: I
authors.initials: I
authors.lastname: Colquhoun
authors.forename: P
authors.initials: P
authors.lastname: Lewis
authors.forename: J M
authors.initials: JM
authors.lastname: Rice-Edwards
authors.forename: R D
authors.initials: RD
authors.lastname: Illingworth
authors.forename: P G
authors.initials: PG
authors.lastname: Richards
mesh_terms: D000328:Adult; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy*; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005910:Glioma / Q000000981:diagnostic imaging / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D015996:Survival Rate; D000077204:Temozolomide; D014057:Tomography, X-Ray Computed
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide